and selectivity to be considered lead structures for drug development. One of the most encouraging is GSK-J1, an inhibitor of the JMJD3 subfamily that binds competitively to the 2-oxoglutarate cofactor and is able to chelate the active site Fe(II) by the pyridine and pyrimidine nitrogens.[100]




GSK-J1

## REFERENCES


1 Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A. *Genes Dev* 2009;**23**:781.
2 For selected reviews, see. (a) Yoo CB, Jones PA. *Nature Rev Drug Discov* 2006;**5**:37; (b) Mair B, Kubicek S, Nijman SMB. *Trends Pharmacol Sci* 2014;**35**:136.
3 For a review, see Helin K, Dhanak D. *Nature* 2013;**502**:480.
4 Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, et al. *Am J Transl Res* 2012;**4**:247.
5 Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, et al. *Clin Cancer Res* 2013;**19**:1.
6 Yoo CB, Cheng JC, Jones PA. *Biochem Soc Trans* 2004;**32**:910.
7 Lyko F, Brown R. *J Natl Cancer Inst* 2005;**97**:1498.
8 For reviews of DNA methyltransferase inhibitors, see. (a) Goffin J, Eisenhauer E. *Ann Oncol* 2002;**13**:1699; (b) Ren J, Singh BN, Huang Q, Li Z, Gao Y, Mishra P, et al. *Cell Signal* 2011;**23**:1082.
9 Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Padzur R. *Oncologist* 2005;**10**:176.
10 Gowher H, Jeltsch A. *Cancer Biol Ther* 2004;**3**:1062.
11 Issa J-P, Kantarjian H. *Nature Rev Drug Discov* 2005;**4**:S6.
12 Kaminskas E, Farrell AT, Abraham S, Baird A, Hsieh L-S, Lee S-L, et al. *Clin Cancer Res* 2005;**11**:3604.
13 Kuykendall JR. *Ann Pharmacother* 2005;**39**:1700.
14 Issa JPJ, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. *J Clin Oncol* 2005;**23**:3948.
15 Qu Z, Fu J, Yan P, Hu J, Cheng SY, Xiao G. *J Biol Chem* 2010;**285**:11786.
16 Xu J, Zhou JY, Tainsky MA, Wu GS. *Cancer Res* 2007;**67**:1203.
17 Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. *Cancer Res* 2006;**66**:2794.
18 https://clinicalstudies.info.nih.gov/detail/A_2006-C-0221.html.
19 Matoušová M, Votruba I, Otmar M, Tloušťvá E, Günterová J, Mertlíková-Kaiserová H. *Epigenetics* 2011;**6**:769.
20 Dhingra HM, Murphy WK, Winn RJ, Raber NM, Hong WK. *Invest New Drugs* 2004;**9**:69.
21 Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. *J Natl Cancer Inst* 2003;**95**:399.
22 Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. *J Mol Biol* 2002;**321**:591.
23 Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. *Cancer Cell* 2004;**6**:151.
24 Jeong LS, Buenger G, McCormack JJ, Cooney DA, Hao Z, Márquez VE. *J Med Chem* 1998;**41**:2572.
25 Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH. *Mol Cancer Ther* 2005;**4**:333.
26 Garcia J, Franci G, Pereira R, Benedetti R, Nebbioso A, Rodríguez-Barrios F. *Bioorg Med Chem* 2011;**19**:3637.